MRK logo

Merck & Co., Inc.

MRK
Healthcare|Drug Manufacturers - General|US
$146.71
-0.23 (-0.16%)
DCF Value
$180.27
Graham Number
$20.09
Cash / Share
$3.89

Analyst Consensus

Buy38 analysts
Strong Buy
0
Buy
26
Hold
11
Sell
1
Strong Sell
0
Consensus Target
$160.47
Implied Upside
+9.4%
Low Target
$105.00
High Target
$180.00

Price Target Trend

Last Month
$162.29
7 targets · +11% vs price
Last Quarter
$162.21
24 targets · +11% vs price
Last Year
$145.80
51 targets · -1% vs price
All Time
$129.44
98 targets · -12% vs price

Rating Trend

Dec 25
17 buy · 13 hold · 0 sell
Jan 26
17 buy · 12 hold · 0 sell
Feb 26
19 buy · 12 hold · 0 sell
Mar 26
19 buy · 11 hold · 0 sell
Apr 26
19 buy · 11 hold · 0 sell
May 26
19 buy · 10 hold · 0 sell
Jun 26
20 buy · 10 hold · 1 sell
Jul 26
19 buy · 9 hold · 1 sell
Aug 26
20 buy · 8 hold · 1 sell
Sep 26
20 buy · 8 hold · 0 sell
Oct 26
19 buy · 9 hold · 0 sell
Nov 26
19 buy · 9 hold · 0 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Nov 2, 2026Cantor FitzgeraldCarter Gould$155.00(+5%)$147.94StreetInsider
Oct 30, 2026GuggenheimVamil Divan$171.00(+17%)$146.33StreetInsider
Oct 30, 2026KeyBanc$165.00(+13%)$146.33StreetInsider
Oct 26, 2026Barclays$180.00(+24%)$145.27TheFly
Oct 22, 2026Wells Fargo$165.00(+12%)$147.24TheFly
Oct 19, 2026Goldman Sachs$155.00(+6%)$146.26TheFly
Oct 12, 2026RBC CapitalTrung Huynh$145.00(-0%)$145.60StreetInsider
Oct 8, 2026Cantor FitzgeraldCarter Gould$145.00(+2%)$142.79StreetInsider
Sep 29, 2026Scotiabank$180.00(+22%)$147.15TheFly
Sep 11, 2026Berenberg BankLuisa Hector$137.00(-5%)$144.71StreetInsider
Sep 10, 2026HSBC$172.00(+17%)$147.60TheFly
Sep 9, 2026Leerink Partners$161.00(+8%)$148.49TheFly
Sep 8, 2026GuggenheimVamil Divan$170.00(+13%)$150.34StreetInsider
Sep 4, 2026Wells Fargo$170.00(+12%)$152.34TheFly
Aug 25, 2026Argus ResearchJasper Hellweg$170.00(+11%)$153.61TheFly
Aug 25, 2026Wolfe ResearchAlexandria Hammond$180.00(+19%)$150.69TheFly
Aug 21, 2026Goldman Sachs$160.00(+7%)$149.25TheFly
Aug 20, 2026BMO Capital$170.00(+14%)$149.65TheFly
Aug 20, 2026UBS$175.00(+15%)$152.22TheFly
Aug 20, 2026RBC Capital$150.00(-1%)$152.22TheFly

Recent Rating Actions

FirmActionRatingDate
Freedom BrokermaintainHoldNov 2, 2026
Cantor FitzgeraldmaintainNeutralNov 2, 2026
GuggenheimmaintainBuyOct 30, 2026
RBC CapitalmaintainSector PerformOct 30, 2026
JP MorganmaintainOverweightOct 30, 2026
BarclaysmaintainOverweightOct 26, 2026
CitigroupmaintainNeutralOct 12, 2026
RBC CapitalmaintainSector PerformOct 12, 2026
Cantor FitzgeraldmaintainNeutralOct 8, 2026
Morgan StanleymaintainOverweightOct 7, 2026
JP MorganmaintainOverweightOct 5, 2026
ScotiabankmaintainSector OutperformSep 29, 2026
HSBCmaintainBuySep 10, 2026
Leerink PartnersmaintainOutperformSep 9, 2026
GuggenheimmaintainBuySep 8, 2026
Wells FargomaintainOverweightSep 4, 2026
Wolfe ResearchmaintainOutperformAug 25, 2026
Argus ResearchmaintainBuyAug 25, 2026
Goldman SachsmaintainBuyAug 21, 2026
Morgan StanleyupgradeEqual Weight →OverweightAug 20, 2026
BMO CapitalmaintainOutperformAug 20, 2026
UBSmaintainBuyAug 20, 2026
RBC CapitaldowngradeOutperform →Sector PerformAug 20, 2026
Daiwa CapitalupgradeNeutral →OutperformAug 12, 2026
Argus ResearchmaintainBuyAug 11, 2026

Earnings History

Next report: Feb 2, 2027 · EPS est. $1.78
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Oct 29, 2026$2.49$2.09$18.09B$17.33B
Aug 4, 2026$-0.13$-0.27$16.61B$16.37B
Apr 30, 2026$-1.28$-1.47$16.29B$15.85B
Feb 3, 2026$2.04$2.01$16.40B$16.20B
Oct 30, 2025$2.58$2.36$17.28B$16.98B
Jul 29, 2025$2.13$2.03$15.81B$15.86B
Apr 24, 2025$2.22$2.13$15.53B$15.34B
Feb 4, 2025$1.72$1.85$15.62B$15.48B

News

Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual Cap

Two men start the same one-minute cancer shot on the same day, yet their Medicare bills will diverge sharply. A hidden enrollment deadline, likely missed years ago, may decide who pays and who doesn't.

Nov 8, 2026247wallst.com
Merck & Co., Inc. $MRK Stock Purchased by Asset One Wealth Management LLC

Asset One Wealth Management LLC boosted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 55.2% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,416 shares of the company's stock after buying an additional 3,706 shares during the period. Asset

Nov 8, 2026defenseworld.net
Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?

MRK's growth momentum faces patent and competitive risks as Keytruda demand and new launches support growth.

Nov 6, 2026zacks.com
Merck & Co., Inc. $MRK Stock Acquired by Compass Financial Management LLC

Compass Financial Management LLC lifted its position in shares of Merck and Co., Inc. (NYSE: MRK) by 256.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,733 shares of the company's stock after purchasing an additional 7,001 shares during the quarter.

Nov 6, 2026defenseworld.net
MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last?

Merck's Keytruda and Gardasil sales rise in Q3, but inventory reversals, slowing demand and looming competition could challenge growth.

Nov 5, 2026zacks.com
Merck & Co., Inc. $MRK Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp cut its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 12.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 393,390 shares of the company's stock after selling 53,672 shares during the period. Boston Trust Walden

Nov 5, 2026defenseworld.net
November Dogs Of The Dow: No Buys, Yet 5 Are Worth Watching

Dow Dogs remain pricey with thin dividends, but 21 of 30 are ‘safer' due to robust free cash flow supporting payouts. Analyst targets project 16.96% to 60.26% net gains for top-ten Dow Dogs by November 2027, though risks and volatility are elevated. None of the top ten Dow Dogs currently meet the ideal dividend-to-price ratio; only Nike achieves 'IDEAL' status but with negative returns and a weak safety margin.

Nov 4, 2026seekingalpha.com
AIA Group Ltd Sells 55,326 Shares of Merck & Co., Inc. $MRK

AIA Group Ltd cut its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 12.3% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 394,399 shares of the company's stock after selling 55,326 shares during the quarter.

Nov 4, 2026defenseworld.net
6,400 Merck & Co., Inc. $MRK Shares Purchased by Aware Super Pty Ltd as trustee of Aware Super

Aware Super Pty Ltd as trustee of Aware Super boosted its stake in Merck and Co., Inc. (NYSE: MRK) by 15.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,294 shares of the company's stock after acquiring an additional

Nov 4, 2026defenseworld.net
Merck gets US FDA emergency use nod for treatment of screwworm in dogs

Merck gets US FDA emergency use nod for treatment of screwworm in dogs

Nov 3, 2026reuters.com
3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressively

In 2022, the last time rates rose quickly, these stocks surged, a couple of them by more than 80%.

Nov 3, 2026fool.com
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.

Nov 3, 2026247wallst.com
Merck's Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.

Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything.

Nov 3, 2026247wallst.com
Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: AON, Bloom Energy, Chevron, Cloudflare, Marvell Technologies, Lumentum Holdings, Merck & Co., Roku, X-Energy, and More

Tech stocks keep beating estimates and then selling off anyway, Apple just joined the club, and Wall Street analysts are busy reshuffling their ratings on everything from nuclear energy plays to insurance giants. Here is who got upgraded, downgraded, and initiated today.

Nov 3, 2026247wallst.com
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients receiving standard of care (SOC) with a history of exacerbations. Recruitment of the ENHANCE-3 trial has begun, and the first patients are now enrolli…

Nov 3, 2026businesswire.com
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs

The market for GLP-1 drugs is forecast to explode. It may be understated still.

Nov 2, 2026fool.com
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN.

Nov 2, 2026businesswire.com
Merck & Co., Inc. $MRK Shares Bought by International Assets Investment Management LLC

International Assets Investment Management LLC raised its position in Merck and Co., Inc. (NYSE: MRK) by 37.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,000 shares of the company's stock after buying an additional 9,608 shares

Nov 2, 2026defenseworld.net
Moderna, Merck eye FDA approval for promising cancer vaccine

Moderna co-founder and board chairman Noubar Afeyan discusses the biotech company's melanoma vaccine trial results and efforts to secure FDA approval on 'The Claman Countdown.' #fox #foxbusiness #media #breakingnews #us #usa #new #news #breaking #theclamancountdown #moderna #merck #nubarafeyan #afeyan #cancer #cancervaccine #melanoma #cancerresearch #cancertreatment #vaccines #biotech #biotechnology #healthcare #healthnews #medicalresearch #clinicaltrials #fda #fdaapproval #immunotherapy #pharma…

Nov 1, 2026youtube.com
Founders Financial Securities LLC Sells 3,449 Shares of Merck & Co., Inc. $MRK

Founders Financial Securities LLC lowered its position in shares of Merck and Co., Inc. (NYSE: MRK) by 17.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,841 shares of the company's stock after selling 3,449 shares during the quarter. Founders Financial

Oct 31, 2026defenseworld.net